All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @genesislifestylemed on TikTok · 30s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @genesislifestylemed's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00One of the main effects of GLP1 receptor agonist,
  2. 0:03like terzepitide, is slowing down the emptying of the stomach
  3. 0:06and reducing food intake by increasing feeling of fullness.
  4. 0:11So this leads to changes in digestion
  5. 0:13and gastrointestinal motility,
  6. 0:15so it slows everything down.
  7. 0:17So this results in symptoms like bloating, gas,
  8. 0:21or flatulence, because the body slowly moves food
  9. 0:25through the GI tract slower than it normally would,
  10. 0:28which allows more gas to build up.

Genesis Lifestyle Medicine's tirzepatide side effects, checked

Genesis Lifestyle Medicine

TikTok creator

63.2K viewsWatch on TikTok

Quick answer

Tirzepatide, a dual GIP and GLP-1 receptor agonist, delays gastric emptying as part of its pharmacological mechanism, which contributes to satiety but also drives gastrointestinal side effects including bloating, nausea, and constipation in a significant portion of users. GI adverse events were among the most common discontinuation reasons in the SURMOUNT-1 trial, occurring in 40-60% of participants at therapeutic doses. These symptoms are generally dose-dependent and tend to attenuate over time with appropriate titration schedules.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Genesis Lifestyle Medicine's tirzepatide side effects, checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Genesis Lifestyle Medicine's tirzepatide side effects, checked" from Genesis Lifestyle Medicine. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delays gastric emptying as part of its pharmacological mechanism, which contributes to satiety but also drives gastrointestinal side effects including bloating, nausea, and constipation in a significant portion of users.

The reason this review is not generic is the source wording and the canonical claim label "glp1 glp 1 receptor agonists like tirzepatide can slow down stoma." In this clip, the useful excerpt is: "One of the main effects of GLP1 receptor agonist, like terzepitide, is slowing down the emptying of the stomach and reducing food intake by increasing feeling of fullness." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GI side effects occurred in roughly 40-60% of tirzepatide participants at higher doses in SURMOUNT-1, making bloating and gas common, not exceptional, complaints.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide, a dual GIP and GLP-1 receptor agonist, delays gastric emptying as part of its pharmacological mechanism, which contributes to satiety but also drives gastrointestinal side effects including bloating, nausea, and constipation in a significant portion of users.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide, a dual GIP and GLP-1 receptor agonist, delays gastric emptying as part of its pharmacological mechanism, which contributes to satiety but also drives gastrointestinal side effects including bloating, nausea, and constipation in a significant portion of users. GI adverse events were among the most common discontinuation reasons in the SURMOUNT-1 trial, occurring in 40-60% of participants at therapeutic doses. These symptoms are generally dose-dependent and tend to attenuate over time with appropriate titration schedules.
  • Delayed gastric emptying is a confirmed pharmacological effect of GLP-1 receptor agonists, documented in clinical trials including SURMOUNT-1 (Jastreboff et al., 2022, NEJM).
  • GI side effects occurred in roughly 40-60% of tirzepatide participants at higher doses in SURMOUNT-1, making bloating and gas common, not exceptional, complaints.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Delayed gastric emptying is a confirmed pharmacological effect of GLP-1 receptor agonists, documented in clinical trials including SURMOUNT-1 (Jastreboff et al., 2022, NEJM).
  • GI side effects occurred in roughly 40-60% of tirzepatide participants at higher doses in SURMOUNT-1, making bloating and gas common, not exceptional, complaints.
  • Slower gastric emptying increases fermentation time in the colon, which is a real biological reason for increased gas production on these medications.
  • GLP-1 receptor agonists do not uniformly slow all GI motility; some patients experience diarrhea, indicating variable effects on lower GI transit.
  • GI symptoms are dose-dependent and typically improve with slow titration schedules and dietary adjustments like eating smaller, lower-fat meals.
  • Tirzepatide is a dual GIP and GLP-1 receptor agonist, technically distinct from pure GLP-1 agonists like semaglutide, with overlapping but not identical side effect profiles.
  • Persistent severe GI symptoms, especially inability to tolerate fluids, should prompt a conversation with a prescriber rather than simple reassurance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @genesislifestylemed actually say?

The creator's claim is straightforward: GLP-1 receptor agonists like tirzepatide slow stomach emptying, reduce food intake by boosting fullness, and that slowdown leads to bloating, gas, and flatulence because food moves through the GI tract more slowly than normal, giving gas more time to accumulate.

There's no dramatic overreach here. No disease cure claims, no dosing advice. Just a mechanistic explanation of why people on these medications feel gassy and bloated. That's actually a reasonable thing to explain to 63,000 viewers, many of whom are probably experiencing exactly those symptoms and wondering why.

One technical note worth flagging: the creator mispronounces tirzepatide as "terzepitide" throughout. Minor point, but worth noting since accuracy in brand-name medications matters when patients are searching for information.

Does the science back this up?

Yes, substantially. The gastroparesis-adjacent effect of GLP-1 receptor agonists is one of the better-documented side effect profiles in this drug class. The creator's core mechanism, slower gastric emptying leading to GI symptoms, is supported by clinical data.

Tirzepatide acts on both GIP and GLP-1 receptors, and GLP-1 receptor activation is well-established as a driver of delayed gastric emptying. Nauck et al. (2021, Diabetes Care) documented gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation as among the most common across GLP-1 receptor agonist trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) specifically tracking tirzepatide in adults with obesity found that GI side effects were reported in roughly 40-60% of participants at higher doses, making these symptoms far from rare.

On the gas and bloating mechanism specifically: slowed intestinal transit does allow for increased fermentation by colonic bacteria, which produces gas. That's basic GI physiology, and the creator's framing is consistent with it.

What did they get wrong (or right)?

They got the broad strokes right. But there's one meaningful omission that matters clinically.

The creator says the body "slowly moves food through the GI tract slower than it normally would." That phrasing is a bit redundant, but more importantly, it flattens a more complex picture. GLP-1 receptor agonists don't uniformly slow the entire GI tract. Gastric emptying slows significantly, but lower GI effects are more variable. Some patients experience diarrhea, which is actually a sign of accelerated colonic transit, not slowed transit. So the "everything slows down" framing is partially inaccurate.

Also missing: any acknowledgment that these symptoms are typically dose-dependent and often improve over time as patients acclimate. Presenting bloating and gas as an inevitable, ongoing consequence without that context could discourage patients from staying on a medication that may be clinically appropriate for them.

Credit where it's due: the creator correctly identifies that tirzepatide is a GLP-1 receptor agonist, correctly links the fullness effect to reduced food intake, and doesn't make any unsupported therapeutic claims.

What should you actually know?

If you're on tirzepatide or another GLP-1 receptor agonist and experiencing bloating or gas, the mechanism the creator describes is real and clinically recognized. But here's what the video leaves out.

  • GI side effects are strongly dose-dependent. Starting low and titrating slowly is the standard approach for minimizing them.
  • Symptoms often improve after the first few weeks as your body adjusts to slower gastric emptying.
  • Eating smaller, lower-fat meals can reduce symptom severity. High-fat foods slow gastric emptying further on top of what the medication is already doing.
  • Persistent or severe GI symptoms, especially if they include vomiting you can't keep fluids down, warrant a conversation with your prescriber, not just tolerance.
  • Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is technically a different mechanism than pure GLP-1 agonists like semaglutide. The GI side effect profiles overlap but are not identical.

The video is a decent starting point for understanding why these symptoms happen. It's not a substitute for talking to the clinician managing your prescription.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Genesis Lifestyle Medicine · TikTok creator

63.2K views on this video

GLP-1 receptor agonists like Tirzepatide can slow down stomach emptying and reduce food intake by increasing the feeling of fullness. This leads to changes in digestion and gastrointestinal motility

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about delayed gastric emptying?

Delayed gastric emptying is a confirmed pharmacological effect of GLP-1 receptor agonists, documented in clinical trials including SURMOUNT-1 (Jastreboff et al., 2022, NEJM).

What does the video say about gi side effects occurred in roughly 40-60% of tirzepatide participants?

GI side effects occurred in roughly 40-60% of tirzepatide participants at higher doses in SURMOUNT-1, making bloating and gas common, not exceptional, complaints.

What does the video say about slower gastric emptying increases fermentation time in the colon,?

Slower gastric emptying increases fermentation time in the colon, which is a real biological reason for increased gas production on these medications.

What does the video say about glp-1 receptor agonists do not uniformly slow all gi motility;?

GLP-1 receptor agonists do not uniformly slow all GI motility; some patients experience diarrhea, indicating variable effects on lower GI transit.

What does the video say about gi symptoms?

GI symptoms are dose-dependent and typically improve with slow titration schedules and dietary adjustments like eating smaller, lower-fat meals.

What does the video say about tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, technically distinct from pure GLP-1 agonists like semaglutide, with overlapping but not identical side effect profiles.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Genesis Lifestyle Medicine, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.